NEW YORK (Jan. 4, 2013) -- A cocktail of three specific genes can reprogram cells in the scars caused
by heart attacks into functioning muscle cells, and the addition of a gene that stimulates the growth of blood vessels enhances that effect, said researchers from Weill Cornell Medical College, Baylor College of Medicine and Stony Brook University Medical Center in a report that appears online in the Journal of the American Heart Association.
"The idea of reprogramming scar tissue in the heart into functioning heart muscle was exciting," said Dr. Todd K. Rosengart, chair of the Michael E. DeBakey Department of Surgery at BCM and the report's corresponding author. "The theory is that if you have a big heart attack, your doctor can just inject these three genes into the scar tissue during surgery and change it back into heart muscle. However, in these animal studies, we found that even the effect is enhanced when combined with the VEGF gene."
"This experiment is a proof of principle," said Dr. Ronald G. Crystal, chairman and professor of genetic medicine at Weill Cornell Medical College and a pioneer ingene therapy, who played an important role in the research. "Now we need to go further to understand the activity of these genes and determine if they are effective in even larger hearts."
During a heart attack, blood supply is cut off to the heart, resulting in the death of heart muscle. The damage leaves behind a scar and a much weakened heart. Eventually, most people who have had serious heart attacks will develop heart failure.
Changing the scar into heart muscle would strengthen the heart. To accomplish this, during surgery,
Rosengart and his colleagues transferred three forms of the vascular endothelial growth factor (VEGF) gene that enhances blood vessel growth or an inactive material (both attached to a gene vector) into the hearts of rats. Three weeks later, the rats received either Gata4, Mef 2c and Tbx5 (the cocktail of transcription factor genes called GMT) or an inactive material. (A transcription factor binds to specific DNA sequences and starts the process that translates the genetic information into a protein.)
The GMT genes alonereduced the amount of scar tissue by half compared to animals that did not
receive the genes, and there were more heart muscle cells in the animals that were treated with GMT. The hearts of animals that received GMT alone also worked better as defined by ejection fraction than those who had not received genes. (Ejection fraction refers to the percentage of blood that is pumped out of a filled ventricle or pumping chamber of the heart.)
The hearts of the animals that had received both the GMT and the VEGF gene transfers had an
ejection fraction four times greater than that of the animals that had received only the GMT transfer.
Rosengart emphasizes that more work needs to be completed to show that the effect of the VEGF is
real, but it has real promise as part of a new treatment for heart attack that would minimize heart damage.
"We have shown both that GMT can effect change that enhances the activity of the heart and that the VEGF gene is effective in improving heart function even more," said Dr. Crystal.
The idea started with the notion of induced pluripotent stem cells – reprograming mature specialized
cells into stem cells that are immature and can differentiate into different specific cells needed in the body. Dr. Shinya Yamanaka and Sir John B. Gurdon received the Nobel Prize in Medicine and Physiology for their work toward this goal this year.
However, use of induced pluripotent stem cells has the potential to cause tumors. To get around that, researchers in Dallas and San Francisco used the GMT cocktail to reprogram the scar cells into cardiomyocytes (cells that become heart muscle) in the living animals.
Now Rosengart and his colleagues have gone a step farther – encouraging the production of new blood
vessels to provide circulation to the new cells.
Others who took part in this work include Megumi Mathison, Ronald Gersch, Ahmed Nasser, Sarit Lilo,
Mallory Korman, Mitchell Fourman, Kenneth Shroyer, Jianchang Yang, Yupo Ma, all
of Stony Brook University Medical
Center and Neil Hackett of Weill Cornell
Funding for this work came from the generosity of James and Lisa Cohen.
medical school located in New York
City, is committed to excellence in research,
teaching, patient care and the advancement of the art and science of medicine,
locally, nationally and globally. Physicians and scientists of Weill Cornell
are engaged in cutting-edge research from bench to bedside, aimed at unlocking
mysteries of the human body in health and sickness and toward developing new
treatments and prevention strategies. In its commitment to global health and
education, Weill Cornell has a strong presence in places such as Qatar, Tanzania,
Haiti, Brazil, Austria and Turkey.
Through the historic Weill Cornell Medical
College in Qatar,
the Medical College
is the first in the U.S.
to offer its M.D. degree overseas. Weill Cornell is the birthplace of many
medical advances -- including the development of the Pap test for cervical
cancer, the synthesis of penicillin, the first successful embryo-biopsy
pregnancy and birth in the U.S., the first clinical trial of gene therapy for
Parkinson's disease, and most recently, the world's first successful use of
deep brain stimulation to treat a minimally conscious brain-injured patient. Weill Cornell
is affiliated with NewYork-Presbyterian
Hospital, where its
faculty provides comprehensive patient care at NewYork-Presbyterian
Hospital/Weill Cornell Medical Center. The Medical
College is also affiliated with the Methodist Hospital
in Houston. For
more information, visit weill.cornell.edu.